This company offers preclinical immunology research services, specializing in study design and management for drug development. Their platform provides deep immunological expertise to assist medical professionals with preclinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery programs targeting immune-related diseases face challenges in efficiently validating targets, optimizing leads, and predicting potential safety liabilities due to the complexity of the immune system and differences between preclinical models and human biology. A significant percentage of clinical trials fail due to poor efficacy, highlighting the need for robust preclinical data that accurately reflects human immune responses.
Solution
Nexus BioQuest is a contract research organization (CRO) providing immunology expertise and agile research solutions to accelerate immune-therapeutic drug discovery programs. They offer a suite of preclinical and non-regulatory clinical biomarker services, including target validation, lead optimization, and predictive immunotoxicology. Nexus BioQuest utilizes relevant cell lines and primary human cells in their assays to evaluate target engagement, mechanism of action, selectivity, and translational biomarkers. They also offer bespoke assay design services to address complex immunological questions and customize research solutions for novel therapeutics.
Target Audience
Nexus BioQuest serves pharmaceutical and biotechnology companies involved in drug discovery and development, particularly those focused on immune-oncology, autoimmunity, inflammation, neuro-inflammation, and vaccine development.
Features
- Target validation in primary human cells and cell lines using flow cytometry and qPCR
- In vitro functional assays to validate the impact of inhibiting or engaging a target
- Lead optimization services using standard and customized assays to assess target engagement, mode of action, and selectivity
- Predictive immunotoxicology services to evaluate cytokine release and off-target events
- Non-regulatory exploratory clinical biomarker services for early phase I/II trials
- 2D and 3D tumor models to study direct or immune-mediated tumor killing
- Capability to work with a wide range of tumor types, including lung, breast, colorectal, and melanoma
- B cell function assays for autoimmunity using tonsil organoid models or peripheral blood